P/TBV of 1.14x (91.06/79.96) against an annualized ROE near 11.6% suggests the market is underwriting an ROTCE in the low double digits with limited re-rating headroom — a fair-value framing rather than a franchise-premium one, in our reading. The 13.39x trailing and 12.36x forward P/E sit below CFR (15.99x) and FFIN (16.95x), a discount that appears to reflect fee lumpiness and execution risk on the strategic pivot rather than a distressed balance sheet, given tangible book grew from $67.75 to $79.96 over ten quarters. We would view the valuation as a work-in-progress pricing: investors are effectively paying near book for a franchise whose earnings power has not yet been demonstrated through a full cycle.

The DuPont decomposition points to leverage (Eq/TA of 0.11, implying ~9.1x assets-to-equity) and the 22.9% fee revenue share doing most of the work, since a 0.9% NIM structurally caps ROA around 0.3% regardless of volume growth. ROE has recovered from -1.9% in 2024Q3 to the 2.0%-2.9% band, but the path is uneven (2.0% in 2026Q1, 2.3% in 2026Q2), suggesting profitability quality is improving without yet becoming dependable. The key judgment for investors is whether the C&I and advisory mix can lift NIM and recurring fee income enough to reduce reliance on gearing — otherwise ROE remains sensitive to any equity build or provision swing.

A 20bp NIM improvement is directionally positive but leaves TCBI well below typical Texas peer margins, and the reported $25B single-quarter asset reclassification in 2026Q3 makes forward NIM trajectory hard to underwrite until earning-asset composition is clarified in subsequent filings. The efficiency ratio's oscillation — 72.4% in 2025Q1 versus 56.0% in 2025Q3 and 65.9% in 2026Q1 versus 57.2% in 2026Q3 — correlates with fee contribution swings from 4.0% to 22.9% of revenue, which suggests operating leverage is real but obscured by deal-flow timing. Investors should monitor whether the recent mid-50s efficiency level holds through a low-fee quarter, as that would be the cleaner test of structural cost control in the talent-heavy model.

CET1, Tier 1, and total capital ratios are not disclosed in the supplied data, so regulatory headroom versus minimums cannot be assessed here; the 11% Eq/TA ratio and tangible book growth from $67.75 to $79.96 per share are the available proxies, and both appear healthy. The combination of a constant equity ratio, retained-earnings accretion, and heavy repurchase activity implies capital return is being funded organically rather than by leverage expansion — a constructive sign, though one that would be constrained if credit costs rise in the Texas CRE book. With a dividend yield of just 0.0%-0.2%, capital return is overwhelmingly discretionary, so buyback pacing should be treated as a management judgment call rather than a committed yield.

TCBI's valuation gap to CFR and FFIN looks partly structural: their higher ROE is achieved on richer deposit franchises and, in CFR's case, a funding advantage that TCBI's 0.9% NIM does not currently replicate, so closing the P/B spread would require demonstrated NIM expansion rather than multiple expansion alone. Cyclical factors cut the other way — Texas GDP and employment strength should support credit quality and loan demand, which may explain why TCBI still commands a premium to SBCF (1.01x P/B, 5.6% ROE) despite similar fee dependence. TCBI's 0.4% dividend yield is the lowest in the group, reinforcing that peers' totals return profiles are more income-oriented while TCBI's is buyback-driven and therefore less visible to income-focused holders.